Breaking News, Financial News

Financial Report: Gilead Sciences

Gilead Sciences

1Q Revenues: $1.3 billion (+22%)

1Q Earnings: $496.1 million (+22%)

Comments: The company achieved record product sales of $1.1 billion (+36%). HIV product sales were $964.7 million in the quarter (+37%). Truvada sales were $479.4 million (+39%), Atripla sales were $324.2 million (+70%), Viread sales were $152.7 million (-5%). Sales of Hepsera for chronic Hepatitis B, were $83.0 million (+16%). Sales of AmBisome were $71.0 million (+15%). R&D expenses in the quarter were $155.3 million (+19%).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters